Copyright
©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Chromogranin A as a valid marker in oncology: Clinical application or false hopes?
Stavros Gkolfinopoulos, Demetris Papamichael, Panteleimon Kountourakis, Department of Medical Oncology, BOC Oncology Center, 2006 Strovolos, Nicosia, Cyprus
Konstantinos Tsapakidis, Department of Medical Oncology, University Hospital of Larissa, 41110 Larissa, Greece
Konstantinos Papadimitriou, Department of Medical Oncology, University Hospital of Antwerp, 2610 Antwerp, Belgium
Author contributions: Gkolfinopoulos S performed the majority of the manuscript preparation; Tsapakidis K contributed to the manuscript preparation; Papadimitriou K contributed to the manuscript preparation; Papamichael D contributed to the manuscript preparation and revision; Kountourakis P contributed to conception, designed the study, coordinated manuscript preparation, prepared the revised version.
Conflict-of-interest statement: There is no conflict of interest on the part of any other authors on this study.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Panteleimon Kountourakis, MD, PhD, Department of Medical Oncology, BOC Oncology Center, 32 Acropoleos Ave, 2006 Strovolos, Nicosia, Cyprus. pantkount@gmail.com
Telephone: +357-22-847402 Fax: +357-22-511870
Received: October 16, 2016
Peer-review started: October 19, 2016
First decision: November 30, 2016
Revised: December 15, 2016
Accepted: January 2, 2017
Article in press: January 4, 2017
Published online: March 26, 2017
Peer-review started: October 19, 2016
First decision: November 30, 2016
Revised: December 15, 2016
Accepted: January 2, 2017
Article in press: January 4, 2017
Published online: March 26, 2017
Core Tip
Core tip: In the era of targeted therapy, there is an unmet need for the development of more sensitive, specific and reliable biomarkers for early diagnosis, prognosis and detection of early recurrence to tumors which comprise an extremely heterogeneous group.